Document is current
Any future updates will be listed below
-
Authors
Haddad, Robert I.
Harrington, Kevin
-
Funding
Funding for this research was provided by:
the healthcare business of Merck KGaA, Darmstadt, Germany
- License Information
-
More Information
Article History
Accepted: 9 September 2024
First Online: 15 October 2024
Declarations
:
: This podcast was funded by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).
: Robert Haddad discloses a consulting or advisory role with Merck, Eisai, Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, EMD Serono, Bayer, Coherus Biosciences, Boehringer Ingelheim, Genmab, Galera Therapeutics, Merus, ALX Oncology; a leadership role with NCCN; stock ownership of Tosk; research funding from Merck, Bristol-Myers Squibb, AstraZeneca, Genentech, Pfizer, Kura Oncology, EMD Serono, Incyte. Kevin Harrington discloses a consulting or advisory role with Arch Oncology, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Serono, MSD, Oncolys BioPharma, Replimune, Inzen Therapeutics, Nanobiotix; speakers bureau for Bristol-Myers Squibb, Merck Serono, MSD; honoraria from Arch Oncology, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Serono, MSD, Oncolys BioPharma, Pfizer, Replimune, Inzen Therapeutics, Codiak Biosciences, Scenic Biotech, Johnson & Johnson, Nanobiotix; research funding with AstraZeneca, Replimune, Boehringer Ingelheim.
: Not applicable
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Both authors meet the International Committee of Medical Journal Editors criteria for authorship for this article, take responsibility for the integrity of the work, and have given their approval for this version to be published.
